Denator AB

Denator successfully completes a 25.5 million SEK financing round with Novo Seeds & Almi Invest as new investors

Press release   •   Mar 26, 2012 07:36 UTC

Denator AB today announced that the company has successfully completed a sixth round of financing, raising 25.5 million SEK (2,75 MEuro). Major contributions came from new investors, Novo Seeds, the early stage investment group of Novo A/S, and the venture capital company, Almi Invest. Existing investors also participated in this round of financing.

In conjunction with the investment, Søren Møller, Managing Investment Director at Novo Seeds, will join the Board of Directors. Mr. Møller explained the background to the Novo Seeds decision: “We are very pleased to co-lead this round with Almi Invest. We believe that Denator’s innovative heat-stabilization technology offer significant value to protein researchers in important areas such as neurodegenerative diseases and cancer. This is Novo Seeds’ first device investment and confirms our continued interest in funding innovative science and entrepreneurship throughout Scandinavia.”

Olof Sköld, CEO at Denator, continued: "We are extremely happy to close this 25,5 million SEK investment and wish to thank our existing investors who have continuously shown their commitment. We also welcome Novo Seeds and Almi Invest to Denator. This funding is an important milestone in our commercial development, and will enable us to strengthen our product development to meet the need our customers and continue our market expansion. We will benefit greatly from the additional resources and experience from our new investors."

 

About Novo Seeds

Novo A/S is the holding and investment company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was formed in 1999 to actively manage the assets of the foundation. It employs about 30 people and has approximately USD 15 billion of assets under management. These includes significant shareholdings in the publicly listed Novo Nordisk A/S (NYSE: NVO) and Novozymes A/S (NVZMF.PK), Novo A/S provides seed, venture and growth capital to development stage companies within life science and biotechnology, as well as manages a broad portfolio of financial assets. Novo A/S is committing up to USD 300 million annually to its investments in seed, venture and growth equity life science companies. Novo Seeds was launched in September 2007 as a new initiative from Novo A/S and the Novo Nordisk Foundation to provide funding for early stage projects and seed financing of new life science companies in Scandinavia.

For more information, visit www.novo.dk

 

About Almi Invest

Almi Invest is a venture capital company investing in Swedish companies with interesting business models and driven entrepreneurs. Almi Invest was launched in 2009 by an initiative from Almi Företagspartner AB together with regional partners. The proceeds that Almi Invest generate over time is turned into new investments, which means that Almi Invest is a so called Evergreen Fund.

For more information, visit www.almiinvest.se

 

About Denator

Denator AB is a privately held biotech company based in Gothenburg, Sweden. Denator develops and markets products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. Based upon the company’s proprietary heat inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and so maintain the stability of sample components throughout the analytical workflow.

 

For more information, please contact:

Olof Sköld

CEO

DenatorAB

E-mail: olof@denator.com

Tel.: +46 31 41 28 90

Fax.: +46 31 41 28 40

 

-----------------------------------------------------------------------------------------------------------------------------

Stabilizor is a trademark ofDenatorAB.